Ratain Irinotecan Insights into the Pharmacokinetics and Pharmacodynamics of

@inproceedings{Ratain2000RatainII,
  title={Ratain Irinotecan Insights into the Pharmacokinetics and Pharmacodynamics of},
  author={Mark J. Ratain},
  year={2000}
}
Irinotecan is a relatively new anticancer agent of interest for both its clinical activity and its complex clinical pharmacology. It is a prodrug, requiring activation by carboxylesterases to SN-38, an inhibitor of topoisomerase I. Recent studies suggest that human carboxylesterase-2 is the primary carboxylesterase involved in the hydrolysis at… CONTINUE READING